PubMed COVID-19 Clinical Care

CONCLUSIONS: The COVIDx-US dataset was released as part of a large open-source initiative, the COVID-Net initiative, and will be continuously growing, as more data sources become available. To the best of the authors' knowledge, COVIDx-US is the

No abstract

No abstract

In the 2 years since the COVID-19 pandemic was officially declared, science has made considerable strides in understanding the disease's pathophysiology, pharmacological treatments, immune response, and vaccination, but there is still much room for

CONCLUSIONS AND RELEVANCE: COVID-19 rebound occurred both after Paxlovid and Molnupiravir, especially in patients with underlying medical conditions. This indicates that COVID-19 rebound is not unique to Paxlovid and the risks were similar for

Despite the significant and rising human and economic costs of the novel coronavirus disease (COVID-19), our knowledge on its epidemiology remains limited necessitating expedited research to aid public policy. This study contributes to the knowledge

CONCLUSION: Post-COVID-19 pulmonary fibrosis is a challenging consequence of COVID-19, and our case suggests that pirfenidone may be an effective treatment option.

The Tokyo 2020 Olympics and Paralympic Games were held in the hottest environment in the history of the games. Additionally, the worldwide coronavirus disease 2019 (COVID-19) pandemic necessitated daily polymerase chain reaction (PCR) testing during

No abstract

CONCLUSIONS AND RELEVANCE: These studies suggest that exercise capacity is reduced after SARS-CoV-2 infection especially among those hospitalized for acute COVID-19 and individuals with LC. Mechanisms for exertional intolerance besides deconditioning